111 Capital Acquires 6,045 Shares of Johnson & Johnson $JNJ

Key Points

• 111 Capital raised its stake in Johnson & Johnson (NYSE: JNJ) by 94% in the second quarter, acquiring an additional 6,045 shares, bringing its total holdings to 12,474 shares valued at approximately $1.9 million.
• Wall Street analysts are optimistic about Johnson & Johnson's prospects, with several firms increasing their price targets, including Wells Fargo, which set a target of $212 and maintains an "overweight" rating on the stock.
• In a significant insider trade, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson valued at over $10 million, reducing her ownership by 24.08%.

111 Capital increased its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 94.0% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 12,474 shares of the company's stock after buying an additional 6,045 shares during the period. 111 Capital's holdings in Johnson & Johnson were worth $1,905,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of JNJ. Highline Wealth Partners LLC raised its stake in Johnson & Johnson by 51.8% in the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock worth $42,000 after buying an additional 86 shares in the last quarter. Stone House Investment Management LLC acquired a new position in shares of Johnson & Johnson during the first quarter worth $47,000. 1248 Management LLC acquired a new position in shares of Johnson & Johnson during the first quarter worth $48,000. von Borstel & Associates Inc. acquired a new position in shares of Johnson & Johnson during the first quarter worth $49,000. Finally, Harvest Fund Management Co. Ltd acquired a new position in shares of Johnson & Johnson during the first quarter worth $52,000. Institutional investors own 69.55% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on JNJ. HSBC upped their price target on Johnson & Johnson from $188.00 to $210.00 in a research report on Tuesday, September 30th. Morgan Stanley upped their price target on Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 17th. Wells Fargo & Company set a $212.00 price target on Johnson & Johnson and gave the stock an "overweight" rating in a research report on Friday. Piper Sandler reissued an "overweight" rating on shares of Johnson & Johnson in a report on Thursday, July 17th. Finally, Guggenheim raised shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and boosted their price objective for the company from $167.00 to $206.00 in a report on Tuesday, September 23rd. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $188.88.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the company's stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.16% of the company's stock.

Johnson & Johnson Price Performance

NYSE:JNJ opened at $188.51 on Monday. Johnson & Johnson has a one year low of $140.68 and a one year high of $189.78. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The firm has a market cap of $453.98 billion, a price-to-earnings ratio of 20.16, a PEG ratio of 2.40 and a beta of 0.40. The firm's fifty day moving average is $176.18 and its two-hundred day moving average is $162.83.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. During the same period in the prior year, the company earned $2.82 earnings per share. The firm's revenue was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Research analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were given a $1.30 dividend. The ex-dividend date was Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.8%. Johnson & Johnson's dividend payout ratio is 55.61%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.